The "International Nonproprietary Name (INN) prescribing project" in Belgium aimed to operationalize electronic INN prescribing for outpatient care in daily medical practice and medical informatics. Patients (or Materials) and Methods: The operationalization process consisted of 3 phases: (1) expert consultation; (2) review by regulatory authorities; and (3) test phase with stakeholders and end-users. Results: The INN prescribing project resulted in: (1) operational rules for electronic INN prescribing; (2) the classification of the therapeutic arsenal, according to the operational rules; and (3) a reference database to be implemented in commercial medical software. The operational rules for electronic INN prescribing define valid INN groups as sets of equivalent medicinal products, described by 3 elements: the therapeutic moiety (the active part of the therapeutic ingredient) or combination of therapeutic moieties, the strength (with standardized denominators), and the method of administration (with simplified but standardized options 
PP058-NEW MEDICINES AND DEVELOPMENT STRATEGIES NECESSITATES CHANGE IN LIFELONG EDUCATION OF CLINICAL PHARMACOLOGY
S. -.-Kerpel-Fronius * Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Introduction: Traditionally, the training in clinical pharmacology concentrated primarily on teaching of rational drug application for students and clinical therapists. Clinical medicines development is another important field of clinical pharmacology that requires a different training approach closely following the emergence of new scientific knowledge. Results: A modern life-long learning concept for clinical pharmacologists must take into consideration the emerging new technologies of medicines development and application. The appearance of highly sensitive and noninvasive technologies to measure pharmacokinetic and pharmacodynamic parameters makes possible drug investigation in humans using extremely low doses without substantial danger for the volunteers at the very early stage of medicines development. These so-called Phase 0 trials permit to enrich the animal results with human pharmacologic data before initiating the classical human Phase I dose escalation study requiring more extensive animal toxicology. In early clinical development of new types of biological medicinal agents, drug-containing nanoparticles, medical device and drug combinations, new pharmaceutical formulations routinely require a team of clinicians and natural scientists to perform jointly the complex tasks of the early learning phase of clinical medicines development. Beside profound knowledge in their primary clinical specialty, the new generation of clinical pharmacologists needs extensive additional training in the new methodologies of drug discovery, molecular biology, immunology, translational medicine, etc. for efficiently functioning in a multidisciplinary team. Conclusion: At the Semmelweis University, the teaching of a reorganized postgraduate training plan for clinical pharmacologists was initiated applying the principles outlined above. On the basis of our experience, an outline for a new national curriculum of clinical pharmacology has been developed, which will be presented. The new plan takes over several topics and concepts worked out during the harmonization of pharmaceutical medicine education in Europe by PharmaTrain. A certain overlap in pharmaceutical medicinal and clinical pharmacological curricula is desired, considering that the optimal clinical application of new types of medicines needs much more basic scientific knowledge than the use of traditional medicinal agents. Disclosure of Interest: None declared. 6 OFAC, Geneva, Switzerland Introduction: Drug manufacturers developed "evergreening strategies" to compete with generic medication after patent termination. These include marketing of slightly modified follow-on drugs (slowrelease formulations, single isomer chiral molecules, active metabolites, or structural analogues/combinations of original patented drugs) and offering high rebates to hospitals that use brand-name or evergreening drugs. The Geneva University Hospitals (HUG) and the Geneva community have different rules indeed. Drug prices are negotiated and prescriptions restricted at HUG, while prices are fixed and prescriptions unrestricted in the community. We examine the impact of listing these drugs in the hospital-restrictive drug formulary (RDF) on the health care system as a whole ("spillover effect").
PP060-PATENTED DRUG EXTENSION STRATEGIES AND HOSPITAL RESTRICTIVE DRUG FORMULARY: A COST-EVALUATION ANALYSIS

Patients (or Materials) and Methods:
We linked hospital and community pharmacy invoice office data in the Swiss canton of Geneva to calculate utilization of 8 follow-on drugs in defined daily doses between 2000 and 2008. This database includes > 73% of the total of insured patients. To examine the financial spillover effect, we calculated a monthly follow-on drug market share in DDDs for medications prescribed by hospital physicians dispensed in the community (eg, at hospital discharge, in outpatient clinics) in comparison to drugs prescribed by physicians in the community. The spillover effect dynamic was analyzed under robust time series analysis using autoregressive integrated moving average (ARIMA) models. 
PP061-RECENT REFORMS IN SCOTLAND TO TAKE ADVANTAGE OF GENERICS, THEIR INFLUENCE AND IMPLICATIONS FOR HEALTH AUTHORITIES CONTEMPLATING FUTURE REFORMS
Conclusion:
Multiple demand-side measures appreciably enhanced prescribing efficiency in Scotland. This was helped by high INN prescribing rates (98% to 99% in all classes studied) and low costs for generics. There was no spillover effect between classes, even if closely related, to enhance the prescribing of generics first line where no active reforms (eg, losartan or risperidone). However, the complexity of treating schizophrenia and bipolar disorders may limit the potential to enhance the prescribing of generic AAPs first line where appropriate.
Study part funded by a grant from Karolinska Institutet. Majority of authors employed by health authorities or are advisers to them. Disclosure of Interest: None declared.
